JP6559566B2 - 癌患者をスクリーニングするための方法及びキット - Google Patents

癌患者をスクリーニングするための方法及びキット Download PDF

Info

Publication number
JP6559566B2
JP6559566B2 JP2015525857A JP2015525857A JP6559566B2 JP 6559566 B2 JP6559566 B2 JP 6559566B2 JP 2015525857 A JP2015525857 A JP 2015525857A JP 2015525857 A JP2015525857 A JP 2015525857A JP 6559566 B2 JP6559566 B2 JP 6559566B2
Authority
JP
Japan
Prior art keywords
patients
gene
response
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015525857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530877A5 (enExample
JP2015530877A (ja
Inventor
ギャロン，ジェローム
パージュ，フランク
ムレチニック，ベルンハルト
ビンデア，ガブリエラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Descartes
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Descartes filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2015530877A publication Critical patent/JP2015530877A/ja
Publication of JP2015530877A5 publication Critical patent/JP2015530877A5/ja
Application granted granted Critical
Publication of JP6559566B2 publication Critical patent/JP6559566B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2015525857A 2012-08-06 2013-08-05 癌患者をスクリーニングするための方法及びキット Active JP6559566B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305975.0 2012-08-06
EP12305975 2012-08-06
PCT/EP2013/066425 WO2014023706A1 (en) 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019131862A Division JP6995091B2 (ja) 2012-08-06 2019-07-17 癌患者をスクリーニングするための方法及びキット

Publications (3)

Publication Number Publication Date
JP2015530877A JP2015530877A (ja) 2015-10-29
JP2015530877A5 JP2015530877A5 (enExample) 2016-09-23
JP6559566B2 true JP6559566B2 (ja) 2019-08-14

Family

ID=46762994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015525857A Active JP6559566B2 (ja) 2012-08-06 2013-08-05 癌患者をスクリーニングするための方法及びキット
JP2019131862A Active JP6995091B2 (ja) 2012-08-06 2019-07-17 癌患者をスクリーニングするための方法及びキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019131862A Active JP6995091B2 (ja) 2012-08-06 2019-07-17 癌患者をスクリーニングするための方法及びキット

Country Status (13)

Country Link
US (2) US20150218650A1 (enExample)
EP (2) EP3470531A1 (enExample)
JP (2) JP6559566B2 (enExample)
AU (1) AU2013301609B2 (enExample)
CA (1) CA2881389C (enExample)
DK (1) DK2880180T3 (enExample)
ES (1) ES2702722T3 (enExample)
LT (1) LT2880180T (enExample)
PL (1) PL2880180T3 (enExample)
PT (1) PT2880180T (enExample)
SG (1) SG11201500922RA (enExample)
TR (1) TR201819211T4 (enExample)
WO (1) WO2014023706A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3232199B1 (en) * 2014-08-19 2022-05-04 National University Corporation Okayama University Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer
WO2016109546A2 (en) * 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
CN109690314B (zh) * 2016-05-09 2022-08-02 法国国家卫生及研究医学协会 患有实体癌症的患者的分类方法
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
JP6565093B1 (ja) 2018-03-22 2019-08-28 住友電工ハードメタル株式会社 表面被覆切削工具およびその製造方法
US20210381058A1 (en) * 2018-10-01 2021-12-09 Nantomics, Llc Evidence based selection of patients for clinical trials using histopathology
WO2020245155A1 (en) 2019-06-03 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating a treatment regimen
IL291748A (en) 2019-11-07 2022-06-01 Oncxerna Therapeutics Inc Classification of growth microenvironments
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4172628A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
WO2022002873A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
CA3245129A1 (en) 2022-03-17 2023-09-21 Univ Paris Cite METHODS FOR PREDICTING RESPONSE TO IMMUNOTHERAPEUTIC TREATMENT IN A CANCER PATIENT

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
US7711492B2 (en) * 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
US20060246524A1 (en) 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
AU2006239315B2 (en) 2005-04-28 2012-03-01 Ventana Medical Systems, Inc. Enzymes conjugated to antiobodies via a PEG heterobifuctional linker
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP3095467B1 (en) 2005-11-23 2020-05-06 Ventana Medical Systems, Inc. Antibody-enzyme conjugate
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
EP2619576B1 (en) * 2010-09-24 2020-06-10 Niels Grabe Means and methods for the prediction of treatment response of a cancer patient
DK3141617T3 (en) * 2011-01-11 2019-02-25 Inst Nat Sante Rech Med PROCEDURE FOR PREVENTING THE CANCER OF A CANCER ON A PATIENT BY ANALYZING GENEPRESSION

Also Published As

Publication number Publication date
WO2014023706A1 (en) 2014-02-13
AU2013301609B2 (en) 2019-03-14
CA2881389A1 (en) 2014-02-13
SG11201500922RA (en) 2015-04-29
DK2880180T3 (en) 2019-01-14
ES2702722T3 (es) 2019-03-05
AU2013301609A1 (en) 2015-02-26
EP3470531A1 (en) 2019-04-17
JP6995091B2 (ja) 2022-01-14
PT2880180T (pt) 2018-12-27
US20150218650A1 (en) 2015-08-06
CA2881389C (en) 2022-01-04
PL2880180T3 (pl) 2019-04-30
JP2015530877A (ja) 2015-10-29
US20200299784A1 (en) 2020-09-24
TR201819211T4 (tr) 2019-01-21
EP2880180A1 (en) 2015-06-10
JP2019176880A (ja) 2019-10-17
LT2880180T (lt) 2019-01-25
EP2880180B1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
JP6559566B2 (ja) 癌患者をスクリーニングするための方法及びキット
JP7378443B2 (ja) 少なくとも７個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法
JP7654318B2 (ja) 固形腫瘍を有する患者をクラス分けするための方法
US20250320564A1 (en) Methods and kits for treatment of cancer patients who are good responders to antitumoral treatment
JP7206203B2 (ja) がんの重症度を評価するためのｔｉｍ－３
JP2022536075A (ja) 処置レジメンを調節する方法
HK40007449A (en) Methods for classifying patients with a solid cancer
HK40007449B (en) Methods for classifying patients with a solid cancer
BR112018072993B1 (pt) Método in vitro para o prognóstico do tempo de sobrevivência de um paciente que sofre de um câncer sólido e método in vitro para avaliar a capacidade de resposta de um paciente que sofre de um câncer sólido a um tratamento antitumoral

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181127

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190108

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190717

R150 Certificate of patent or registration of utility model

Ref document number: 6559566

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250